JP6745873B2 - 神経変性における治療標的としての細胞外ｄｎａ - Google Patents

神経変性における治療標的としての細胞外ｄｎａ Download PDF

Info

Publication number
JP6745873B2
JP6745873B2 JP2018513264A JP2018513264A JP6745873B2 JP 6745873 B2 JP6745873 B2 JP 6745873B2 JP 2018513264 A JP2018513264 A JP 2018513264A JP 2018513264 A JP2018513264 A JP 2018513264A JP 6745873 B2 JP6745873 B2 JP 6745873B2
Authority
JP
Japan
Prior art keywords
dnase
pharmaceutical composition
composition according
disease
neurodegeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018513264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520208A (ja
JP2018520208A5 (https=
Inventor
ドミトリエヴィッチ ゲンキン，ドミトリー
ドミトリエヴィッチ ゲンキン，ドミトリー
ヴィクトロヴィッチ テッツ，ゲオルギー
ヴィクトロヴィッチ テッツ，ゲオルギー
ヴェニアミノヴィッチ テッツ，ヴィクター
ヴェニアミノヴィッチ テッツ，ヴィクター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018520208A publication Critical patent/JP2018520208A/ja
Publication of JP2018520208A5 publication Critical patent/JP2018520208A5/ja
Application granted granted Critical
Publication of JP6745873B2 publication Critical patent/JP6745873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C12Y301/02021—Dodecanoyl-[acyl-carrier-protein] hydrolase (3.1.2.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018513264A 2015-05-22 2016-05-11 神経変性における治療標的としての細胞外ｄｎａ Active JP6745873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165255P 2015-05-22 2015-05-22
US62/165,255 2015-05-22
PCT/RU2016/000284 WO2016190780A1 (en) 2015-05-22 2016-05-11 Extracellular dna as a therapeutic target in neurodegeneration

Publications (3)

Publication Number Publication Date
JP2018520208A JP2018520208A (ja) 2018-07-26
JP2018520208A5 JP2018520208A5 (https=) 2019-09-19
JP6745873B2 true JP6745873B2 (ja) 2020-08-26

Family

ID=57393467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513264A Active JP6745873B2 (ja) 2015-05-22 2016-05-11 神経変性における治療標的としての細胞外ｄｎａ

Country Status (7)

Country Link
US (1) US11701410B2 (https=)
EP (1) EP3297657B1 (https=)
JP (1) JP6745873B2 (https=)
CN (1) CN108289932A (https=)
ES (1) ES2799515T3 (https=)
RU (1) RU2726131C2 (https=)
WO (1) WO2016190780A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
WO2018197547A1 (en) * 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
EP3634442B1 (en) 2017-05-24 2025-04-09 Tets, Viktor, Veniaminovich Method for diagnosis of parkinson's disease
WO2019053243A1 (en) 2017-09-18 2019-03-21 Santersus Sa METHOD AND DEVICE FOR PURIFYING BLOOD OF FREE CIRCULATING DNA
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US12535491B2 (en) 2018-04-30 2026-01-27 Viktor Veniaminovich Tets Vaccine comprising protein-targeted (PT) extracellular DNA isolated from bacterial matrix
US11918610B2 (en) 2018-06-29 2024-03-05 Viktor Veniaminovich Tets Methods for diagnosis and treatment of type 1 diabetes
US12480150B2 (en) 2018-06-29 2025-11-25 Viktor Veniaminovich Tets and Georgy Viktorovich TETS Compositions for modulating gut microbiota
WO2020010214A1 (en) 2018-07-03 2020-01-09 Tets Viktor Veniaminovich Method for assessing and inhibiting aging and means of determining biological age
CN110129245B (zh) * 2019-07-08 2020-12-04 南京工业大学 一株敲除胞外核酸酶ExeP的谷氨酸棒杆菌及其构建方法与应用
WO2021011368A1 (en) * 2019-07-12 2021-01-21 Dmitry Dmitrievich Genkin Treatment of diseases associated with protein misfolding by nervous system expression of an enzyme which has a deoxyribonuclease (dnase) activity
EP4119149A1 (en) * 2021-07-15 2023-01-18 Foundation For Research And Technology Hellas Extracellular vesicles comprising a therapeutic cargo
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224942A (en) 1962-01-15 1965-12-21 Rorer Inc William H Anti-inflammatory, anti-edema and anti-thrombi drug
US3324002A (en) 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS61293927A (ja) 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
EP0449968B1 (en) 1988-12-23 1999-02-24 Genentech, Inc. Process for the preparation of human dnase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE4024530A1 (de) 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
FR2666096B1 (fr) 1990-08-21 1993-12-31 Sfri Sa Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US5484589A (en) 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
AU7212694A (en) 1993-06-24 1995-01-17 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
ATE268605T1 (de) 1994-03-04 2004-06-15 Genentech Inc Pharmazeutische akzeptabel dnase zusammensetzung
US5830744A (en) 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
DE69533987T2 (de) 1994-05-20 2006-03-16 Hisamitsu Pharmaceutical Co., Inc., Tosu Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte
NZ331063A (en) 1996-02-05 2000-03-27 Inc Genentech Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
AU2324997A (en) 1996-03-15 1997-10-01 Penn State Research Foundation, The Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6242426B1 (en) 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6455250B1 (en) 1997-12-11 2002-09-24 The Regents Of The University Of California Endonuclease compositions and methods of use
NZ509273A (en) 1998-07-16 2003-05-30 Res Dev Foundation DNA-cleaving antitumor agents containing a benzimidazole derivative
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
JP2002530436A (ja) 1998-11-25 2002-09-17 ジェネティカ インコーポレイテッド 増殖能を増強しかつ複製老化を防止する方法及び試薬
JP2000229881A (ja) 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
WO2001012793A1 (en) 1999-08-17 2001-02-22 Tanuma Sei Ichi Novel deoxyribonuclease, gene encoding the same and use thereof
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
WO2001074905A1 (en) 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
US6462017B1 (en) 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
RU2202109C1 (ru) 2001-08-03 2003-04-10 Научно-исследовательский институт неврологии РАН Способ выявления степени нарушения реологических свойств крови
RU2207876C1 (ru) 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
CA2516322C (en) * 2002-02-18 2013-10-15 University Of Southampton Glycosaminoglycan-dnase combination therapy
DE10221194B4 (de) 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
DE60219809T2 (de) 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
RU2239442C1 (ru) 2003-05-05 2004-11-10 Красноярская государственная медицинская академия Способ профилактики внутриутробных инфекций у детей
WO2005004904A1 (en) 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants)
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
AU2003298972A1 (en) 2003-07-14 2005-02-04 Dmitry Dmitrievich Genkin Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
RU2269359C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
RU2239404C1 (ru) 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Способ профилактики старения организма человека
RU2267329C2 (ru) 2004-03-12 2006-01-10 Дмитрий Дмитриевич Генкин Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты)
RU2269357C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека
US9592277B2 (en) 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
ES2665422T3 (es) * 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
JP3989936B2 (ja) 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
EP2484768A3 (en) 2005-07-18 2012-11-21 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
RU2308968C2 (ru) 2005-07-19 2007-10-27 Дмитрий Дмитриевич Генкин Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации
WO2008039989A2 (en) 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
EP2416156B1 (en) 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
US8871200B2 (en) 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
CA2814962A1 (en) * 2010-12-02 2012-06-07 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US20130243794A1 (en) 2010-12-03 2013-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
MX367100B (es) 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
KR102082735B1 (ko) 2012-08-03 2020-02-28 훼링 비.브이. 암컷 불임에 대한 치료학적 타겟 및 진단 마커로서의 세포-유리 dna
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
AU2015234242B2 (en) 2014-03-21 2020-09-24 Children's Medical Research Institute Stable gene transfer to proliferating cells
EP4344741A3 (en) 2014-11-21 2024-08-28 The University of North Carolina at Chapel Hill Aav vectors targeted to the central nervous system
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
SG11201802408RA (en) 2015-11-05 2018-05-30 Bamboo Therapeutics Inc Modified friedreich ataxia genes and vectors for gene therapy
EP3420077A4 (en) 2016-02-25 2019-12-25 Agenovir Corporation VIRAL AND ONCOVIRAL NUCLEASE TREATMENT

Also Published As

Publication number Publication date
RU2017145051A3 (https=) 2019-06-24
US20180360925A1 (en) 2018-12-20
EP3297657A4 (en) 2018-11-14
ES2799515T3 (es) 2020-12-18
JP2018520208A (ja) 2018-07-26
US11701410B2 (en) 2023-07-18
RU2017145051A (ru) 2019-06-24
EP3297657A1 (en) 2018-03-28
RU2726131C2 (ru) 2020-07-09
CN108289932A (zh) 2018-07-17
WO2016190780A1 (en) 2016-12-01
EP3297657B1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
JP6745873B2 (ja) 神経変性における治療標的としての細胞外ｄｎａ
Xie et al. Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ
Wang et al. Progress of immunotherapy of anti-α-synuclein in Parkinson’s disease
US20260034156A1 (en) Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
Hwang et al. Microglia signaling as a target of donepezil
CN113164508B (zh) 与神经保护剂组合的sarm1抑制剂
US12595481B2 (en) Methods and compositions for neuroprotection
EP3074034B1 (en) Treatment of inflammatory disease using caveolin linked to an internalisation peptide
US20240100076A1 (en) Methods and compositions for treating neurodegenerative diseases
Claeys et al. Epilepsy and migraine in a patient with Urbach–Wiethe disease
CN120310791A (zh) 靶向α-突触核蛋白的反义寡核苷酸及其用途
Bahat et al. Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression
CN118593706A (zh) 通过调节Endoglin治疗痴呆的方法
CN100525764C (zh) 吡唑并吡啶在制备治疗认知缺陷的药物中的应用
Ishigaki et al. Fukuyama congenital muscular dystrophy: clinical features and therapeutic advances
JP2005247728A (ja) 医薬組成物
AU2024260719A1 (en) Mivelsiran compositions and methods of use thereof
Tsukamoto Targeting enzymes in the brain
Croasdell Alzheimer’s Association International Conference 2020
Croasdell Alzheimer
Parsons et al. P4-362 Statins reduce β-amyloid production but increase its release from the cell
CN121015894A (zh) 一种用于治疗退行性疾病的药物组合物及其应用
Zhang et al. P4-363 Chinese herb component SSY-P3 protects against abnormality in animal models of Alzheimer's disease
Matthews Statin therapy correlates with improved outcomes following carotid endarterectomy
Phoebe et al. Qi Li*, Wai Man Chan, John A. Rudd⁺, Chun Mei Wang Phoebe Y. H. Lam

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200804

R150 Certificate of patent or registration of utility model

Ref document number: 6745873

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250